Indegene is into Healthcare & Pharmaceuticals Lifesciences and is looking raise funds through Fresh Issue and Offer For Sale
Indegene IPO: Indegene Limited has filed Draft Red Herring Prospectus (DRHP) for proposed initial public offer (IPO) and raise funds through an offer of equity share capital having face value of Rs. 2 per share via initial public offering.
Promoters of Indegene are The Company is a professionally managed company and does not have an identifiable promoter. and holds 0% stake in the company.
Key Details:
- Initial Public Offer comprising of a Fresh Issue of Equity shares aggregating up to Rs 950 Cr and an Offer for Sale of up to 36,291,497 Equity Shares.
- Kotak Mahindra Capital, Citigroup Global, J.P.Morgan, Nomura Financial have been appointed as lead merchant bankers for the proposed IPO.
- It has appointed Link Intime (India) Pvt. Ltd. as Registrar and Share transfer Agent.
- Company is yet to finalize issue size and some other important details relating to the IPO.
Details about upcoming IPO:
As per the details available in DRHP, fundraising will consist of an Fresh Issue aggregating Rs. 950 Crs and offer-for-sale (OFS) of up to 36,291,497 equity shares by Offer for sale comprises of individual and investors selling shareholders selling upto 36,291,497 shares. More details are available in DRHP / RHP...
Objects of the issue:
1) Repayment / pre=payment of debt of one of the subsidiaries, 2) Funding the capex requirements of the company and subsidiaries., and 3) General corporate purpose and inorganic growth..
About Company:
Indegene is a digital-first, life sciences commercialization company. Company help biopharmaceutical, emerging biotech, and medical device companies develop products, bring them to market, and enhance their impact throughout the product life cycle. They achieve this through a combination of healthcare domain expertise, fit-for-purpose technology, and an agile operating model. Indegene’s solutions aim to deliver personalized, scalable, and omnichannel experiences for both patients and physicians. With a global team of over 5,000 members across 17 offices, they have earned the trust of 20 out of the top global pharmaceutical companies. As on Q3FY24, company had 65 active clients.
About Industry:
The life sciences industry primarily comprises biopharmaceutical companies and medical devices companies, whose combined sales were estimated at ₹138.3 trillion (US$1.8 trillion) in 2023, with biopharmaceutical companies constituting 69% or ₹95.4 trillion (US$1.2 trillion) of such sales. Combined sales of biopharmaceutical companies and medical devices companies are estimated to reach ₹163.5 trillion (US$2.1 trillion) by 2026 driven by a rise in aging population, increasing prevalence of chronic diseases and discovery of new diseases, among other factors. Life sciences operations expenditure (which includes spends on marketing and sales, drug discovery and clinical trials, regulatory and medical affairs, manufacturing, supply chain and distribution and pharmacovigilance or complaints management) was estimated at ₹12.0 trillion (US$156 billion) in 2022 and is expected to grow at a CAGR of 6.5% to reach ₹15.5 trillion (US$201 billion) in 2026 in line with growth in industry sales.
Source: SEBI, BSE, NSE, DRHP, Indegene, Industry Data
Disclaimer: Above article only publishes details about the IPO for educational purpose and doesn't solicit or invite any interest to invest. Please visit respective sources to verify and know more details about the IPO. We advise investors to take opinion from certified/SEBI registered experts before taking any investment decisions.
Posts
0 Comments